James Duckenfield, CEO of Glass Pharms®, explains why we may be underestimating the pharmaceutical potential of cannabis, and how research, formulation and more controlled delivery could help realise it.
In April 2025, the Italian government used emergency constitutional powers to bypass parliament and reclassify non-intoxicating hemp as a narcotic, regardless of THC content, following multiple failed attempts to decimate the industry.
New Zealand’s medical cannabis market grew a further 25% in 2025, according to the latest official figures, seeing the country cement its position as one of the lesser-discussed but most exciting markets on the planet.
Sorting Evidence from Anecdote As global cannabis research accelerates, the number of published studies has never been higher, but not all evidence carries the same scientific weight.
Cannabis is now one of the most frequently discussed therapeutic agents in modern medicine, driven by expanding access programmes and a growing demand for alternatives to conventional pharmaceuticals.
Legal cannabis cultivators like Bovenschen’s Pure Sunfarms are required by law to label every flower product with its total THC content, measured “in discrete units.” That’s despite a recent study showing cannabis flower’s THC content can vary by as much as one-third – even within the same plant.
Slovenia is making its own move toward legalisation, at least in part, for personal consumption. As reported two weeks ago by the Slovenian news agency Index, members of Slovenia’s governing coalition, comprising the Freedom Movement (Gibanje Svoboda) and the Left (Levica), have submitted a draft bill to parliament aimed at regulating personal cannabis use. Natasa Sukic, a member of parliament from Levica, said the goal is to implement the will of the voters.
This morning, the UK’s Food Standards Agency (FSA) announced some significant updates to its multi-year CBD Novel Foods approvals process, finally offering hundreds of long-suffering businesses some light at the end of the tunnel.
One of the key differences between medical cannabis and other more traditional treatments is the highly personalised nature of how each patient is affected.
